Telomeres in glioma: Maintenance mechanisms to therapeutic potential.
作者信息
Stevers Nicholas O, Costello Joseph F
机构信息
Department of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.
出版信息
Neuro Oncol. 2024 Jun 3;26(6):1025-1026. doi: 10.1093/neuonc/noae052.
Abstract
摘要
相似文献
1
Telomeres in glioma: Maintenance mechanisms to therapeutic potential.
Neuro Oncol. 2024 Jun 3;26(6):1025-1026. doi: 10.1093/neuonc/noae052.
2
Mechanisms of telomere maintenance and associated therapeutic vulnerabilities in malignant gliomas.
Neuro Oncol. 2024 Jun 3;26(6):1012-1024. doi: 10.1093/neuonc/noae016.
3
Induced Telomere Damage to Treat Telomerase Expressing Therapy-Resistant Pediatric Brain Tumors.
Mol Cancer Ther. 2018 Jul;17(7):1504-1514. doi: 10.1158/1535-7163.MCT-17-0792. Epub 2018 Apr 13.
4
5
Non-invasive assessment of telomere maintenance mechanisms in brain tumors.
Nat Commun. 2021 Jan 4;12(1):92. doi: 10.1038/s41467-020-20312-y.
6
When the Ends Are Really the Beginnings: Targeting Telomerase for Treatment of GBM.
Curr Neurol Neurosci Rep. 2018 Mar 10;18(4):15. doi: 10.1007/s11910-018-0825-7.
7
Telomere 3' overhang-specific DNA oligonucleotides induce autophagy in malignant glioma cells.
FASEB J. 2007 Sep;21(11):2918-30. doi: 10.1096/fj.06-6941com. Epub 2007 Apr 20.
8
Genetic variants in telomerase-related genes are associated with an older age at diagnosis in glioma patients: evidence for distinct pathways of gliomagenesis.
Neuro Oncol. 2013 Aug;15(8):1041-7. doi: 10.1093/neuonc/not051. Epub 2013 Jun 3.
9
Prognostic significance of telomere maintenance mechanisms in pediatric high-grade gliomas.
J Neurooncol. 2014 Mar;117(1):67-76. doi: 10.1007/s11060-014-1374-9. Epub 2014 Jan 30.
10
A preclinical mouse model of glioma with an alternative mechanism of telomere maintenance (ALT).
Int J Cancer. 2015 Apr 1;136(7):1546-58. doi: 10.1002/ijc.29171. Epub 2014 Sep 11.
引用本文的文献
1
Vaccines for cancer prevention: exploring opportunities and navigating challenges.
Nat Rev Drug Discov. 2025 Feb;24(2):134-150. doi: 10.1038/s41573-024-01081-5. Epub 2024 Dec 2.
本文引用的文献
1
Mechanisms of telomere maintenance and associated therapeutic vulnerabilities in malignant gliomas.
Neuro Oncol. 2024 Jun 3;26(6):1012-1024. doi: 10.1093/neuonc/noae016.
2
Whole tumor analysis reveals early origin of the TERT promoter mutation and intercellular heterogeneity in TERT expression.
Neuro Oncol. 2024 Apr 5;26(4):640-652. doi: 10.1093/neuonc/noad231.
3
A pan-sarcoma landscape of telomeric content shows that alterations in RAD51B and GID4 are associated with higher telomeric content.
NPJ Genom Med. 2023 Sep 14;8(1):26. doi: 10.1038/s41525-023-00369-6.
4
Telomerase as a therapeutic target in glioblastoma.
Neuro Oncol. 2021 Dec 1;23(12):2004-2013. doi: 10.1093/neuonc/noab203.
5
A method for measuring the distribution of the shortest telomeres in cells and tissues.
Nat Commun. 2017 Nov 7;8(1):1356. doi: 10.1038/s41467-017-01291-z.
6
Hallmarks of cancer: the next generation.
Cell. 2011 Mar 4;144(5):646-74. doi: 10.1016/j.cell.2011.02.013.
7
The shortest telomere, not average telomere length, is critical for cell viability and chromosome stability.
Cell. 2001 Oct 5;107(1):67-77. doi: 10.1016/s0092-8674(01)00504-9.
Zotero 插件